KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Treasury Shares (2016 - 2025)

Moderna (MRNA) has disclosed Treasury Shares for 7 consecutive years, with $8.0 million as the latest value for Q4 2023.

  • On a quarterly basis, Treasury Shares fell 65.22% to $8.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $8.0 million, a 65.22% decrease, with the full-year FY2023 number at $8.0 million, down 65.22% from a year prior.
  • Treasury Shares was $8.0 million for Q4 2023 at Moderna, roughly flat from $8.0 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $23.0 million in Q4 2022 to a low of $1.0 million in Q1 2019.
  • A 5-year average of $5.4 million and a median of $2.4 million in 2021 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 792.86% in 2022, then crashed 69.23% in 2023.
  • Moderna's Treasury Shares stood at $1.2 million in 2019, then skyrocketed by 86.03% to $2.2 million in 2020, then skyrocketed by 36.99% to $3.0 million in 2021, then surged by 666.67% to $23.0 million in 2022, then crashed by 65.22% to $8.0 million in 2023.
  • Per Business Quant, the three most recent readings for MRNA's Treasury Shares are $8.0 million (Q4 2023), $8.0 million (Q3 2023), and $4.0 million (Q2 2023).